Highlights of the 2008 International Conference on Malignant Lymphoma.

1. Xagrid Summary of Product Characteristics, July 2014 2. Hong Y et al. Platelets. 2002 3. Petrides et al. Expert Opin Pharmacother 2004 4. Barosi G, Leukemia. 2007 Feb;21(2):277–80 Non-cytotoxic activity that allows long-term clinical use: no known mutagenic, clastogenic or leukemogenic properties1-3 If, with first-line HU: • The patient does not achieve an adequate response: if the platelet count has not reduced to ≤600 x 109/l after 3 months of HU (or ≤400 x 109/l where there is a low white blood count or low haemoglobin)4 • The patient is HU-intolerant: a range of side effects (particularly leukopenia, anaemia, leg ulcers, other muco-cutaneous manifestations and fever) may become unacceptable.4